Angiotensin II receptor antagonists in acute coronary syndromes.

摘要: Background It is well known that inappropriate or exaggerated activity of the renin-angiotensin system might contribute to development systemic hypertension with consequent organ injury and associated increased risk acute cardiovascular (CV) diseases. This review will discuss evidence form basic research clinical studies, investigating efficacy angiotensin II receptor blockers (ARBs) in management coronary syndromes (ACS). Materials methods This narrative based on material found MEDLINE PubMed up June 2013. We looked for terms ‘angiotensin, AT1 receptor, ACE inhibitors’ combination ‘acute syndromes, myocardial infarction, pathophysiology’. Results Preclinical studies showed relevant protective effects ARBs reduce adverse cardiac remodelling animal models ischaemia. However, although recommended Consensus guidelines as a good alternative angiotensin-converting enzyme inhibitors (ACEIs), did not confirm superior compared ACEIs. As matter fact some authors, these drugs potentially have deleterious increasing CV risk. Conclusions Emerging from trials suggests use ACS be controversial, caution should used their replace ACEIs ACS.